Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
PSDV's Cash to Debt is ranked higher than
99% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. PSDV: No Debt )
Ranked among companies with meaningful Cash to Debt only.
PSDV' s Cash to Debt Range Over the Past 10 Years
Min: 0.47  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.60
PSDV's Equity to Asset is ranked higher than
61% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. PSDV: 0.60 )
Ranked among companies with meaningful Equity to Asset only.
PSDV' s Equity to Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.71 Max: 0.91
Current: 0.6
0.47
0.91
Interest Coverage No Debt
PSDV's Interest Coverage is ranked higher than
98% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. PSDV: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PSDV' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 4
Z-Score: -9.29
M-Score: -12.11
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1184.15
PSDV's Operating margin (%) is ranked lower than
96% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. PSDV: -1184.15 )
Ranked among companies with meaningful Operating margin (%) only.
PSDV' s Operating margin (%) Range Over the Past 10 Years
Min: -2445.54  Med: -474.92 Max: 39.44
Current: -1184.15
-2445.54
39.44
Net-margin (%) -1171.95
PSDV's Net-margin (%) is ranked lower than
96% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. PSDV: -1171.95 )
Ranked among companies with meaningful Net-margin (%) only.
PSDV' s Net-margin (%) Range Over the Past 10 Years
Min: -4638.7  Med: -469.92 Max: 37.97
Current: -1171.95
-4638.7
37.97
ROE (%) -86.79
PSDV's ROE (%) is ranked lower than
91% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. PSDV: -86.79 )
Ranked among companies with meaningful ROE (%) only.
PSDV' s ROE (%) Range Over the Past 10 Years
Min: -133.19  Med: -60.80 Max: 33.15
Current: -86.79
-133.19
33.15
ROA (%) -63.46
PSDV's ROA (%) is ranked lower than
92% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. PSDV: -63.46 )
Ranked among companies with meaningful ROA (%) only.
PSDV' s ROA (%) Range Over the Past 10 Years
Min: -95.61  Med: -41.87 Max: 23.06
Current: -63.46
-95.61
23.06
ROC (Joel Greenblatt) (%) -6770.50
PSDV's ROC (Joel Greenblatt) (%) is ranked lower than
86% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. PSDV: -6770.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PSDV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -15359.59  Med: -5174.70 Max: 16680.73
Current: -6770.5
-15359.59
16680.73
Revenue Growth (3Y)(%) 72.30
PSDV's Revenue Growth (3Y)(%) is ranked higher than
97% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. PSDV: 72.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PSDV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -58.1  Med: 16.60 Max: 85
Current: 72.3
-58.1
85
» PSDV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

PSDV Guru Trades in Q1 2015

Jim Simons 194,800 sh (+184.80%)
» More
Q2 2015

PSDV Guru Trades in Q2 2015

Jim Simons 316,234 sh (+62.34%)
» More
Q3 2015

PSDV Guru Trades in Q3 2015

Ken Fisher 12,057 sh (New)
Jim Simons 434,819 sh (+37.50%)
» More
Q4 2015

PSDV Guru Trades in Q4 2015

Ken Fisher 12,057 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with PSDV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.64
PSDV's P/B is ranked lower than
80% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.38 vs. PSDV: 4.64 )
Ranked among companies with meaningful P/B only.
PSDV' s P/B Range Over the Past 10 Years
Min: 0.01  Med: 2.59 Max: 11.73
Current: 4.64
0.01
11.73
P/S 51.94
PSDV's P/S is ranked lower than
99.99% of the 937 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.68 vs. PSDV: 51.94 )
Ranked among companies with meaningful P/S only.
PSDV' s P/S Range Over the Past 10 Years
Min: 0.38  Med: 11.36 Max: 1600
Current: 51.94
0.38
1600
PFCF 8.98
PSDV's PFCF is ranked higher than
91% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.80 vs. PSDV: 8.98 )
Ranked among companies with meaningful PFCF only.
PSDV' s PFCF Range Over the Past 10 Years
Min: 8.98  Med: 11.51 Max: 105
Current: 8.98
8.98
105
POCF 8.69
PSDV's POCF is ranked higher than
87% of the 631 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 21.19 vs. PSDV: 8.69 )
Ranked among companies with meaningful POCF only.
PSDV' s POCF Range Over the Past 10 Years
Min: 7.11  Med: 10.94 Max: 35
Current: 8.69
7.11
35
Current Ratio 8.41
PSDV's Current Ratio is ranked higher than
89% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. PSDV: 8.41 )
Ranked among companies with meaningful Current Ratio only.
PSDV' s Current Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.58 Max: 17.6
Current: 8.41
0.26
17.6
Quick Ratio 8.41
PSDV's Quick Ratio is ranked higher than
89% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. PSDV: 8.41 )
Ranked among companies with meaningful Quick Ratio only.
PSDV' s Quick Ratio Range Over the Past 10 Years
Min: 0.26  Med: 5.58 Max: 17.6
Current: 8.41
0.26
17.6
Days Sales Outstanding 120.47
PSDV's Days Sales Outstanding is ranked lower than
76% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. PSDV: 120.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
PSDV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.55  Med: 81.04 Max: 493.85
Current: 120.47
8.55
493.85

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.69
PSDV's Price/Net Cash is ranked higher than
67% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.70 vs. PSDV: 5.69 )
Ranked among companies with meaningful Price/Net Cash only.
PSDV' s Price/Net Cash Range Over the Past 10 Years
Min: 0.45  Med: 6.85 Max: 246
Current: 5.69
0.45
246
Price/Net Current Asset Value 5.29
PSDV's Price/Net Current Asset Value is ranked higher than
65% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.29 vs. PSDV: 5.29 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
PSDV' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.16  Med: 5.68 Max: 98.4
Current: 5.29
0.16
98.4
Price/Tangible Book 5.10
PSDV's Price/Tangible Book is ranked lower than
59% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. PSDV: 5.10 )
Ranked among companies with meaningful Price/Tangible Book only.
PSDV' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.15  Med: 5.63 Max: 33.7
Current: 5.1
0.15
33.7
Price/Median PS Value 4.35
PSDV's Price/Median PS Value is ranked higher than
91% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.14 vs. PSDV: 4.35 )
Ranked among companies with meaningful Price/Median PS Value only.
PSDV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.07  Med: 0.97 Max: 118.26
Current: 4.35
0.07
118.26
Price/Graham Number 1.67
PSDV's Price/Graham Number is ranked higher than
63% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.18 vs. PSDV: 1.67 )
Ranked among companies with meaningful Price/Graham Number only.
PSDV' s Price/Graham Number Range Over the Past 10 Years
Min: 0.05  Med: 1.64 Max: 4.6
Current: 1.67
0.05
4.6
Earnings Yield (Greenblatt) (%) -30.54
PSDV's Earnings Yield (Greenblatt) (%) is ranked lower than
92% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. PSDV: -30.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PSDV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -30.54  Med: 7.40 Max: 18.4
Current: -30.54
-30.54
18.4

More Statistics

Revenue(Mil) $2
EPS $ -0.66
Beta0.98
Short Percentage of Float3.73%
52-Week Range $2.80 - 5.81
Shares Outstanding(Mil)29.42

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PVA.Australia, PV3.Germany, PSIZF.USA,
pSivida Corp was organized as a Delaware Corporation in March 2008. The Company develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. It is engaged in the treatment of chronic diseases of the back of the eye utilizing its core technology platforms, Durasert and BioSilicon. It currently has three approved products, as well as two current product candidates in clinical trials and uses different generations of this technology system. It has developed three of the four sustained release devices for treatment of retinal diseases currently approved in the U.S. or the European Union (EU). ILUVIEN, its recently approved product, is an injectable, sustained-release micro-insert that provides treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies over a period of up to three years. ILUVIEN is being developed by its licensee Alimera Sciences, Inc. (Alimera). ILUVIEN has received marketing authorization in the United Kingdom, Austria, France, Germany and Portugal and marketing authorization is pending in Italy and Spain. Alimera is also seeking marketing approval for ILUVIEN for DME in the U.S. Alimera has announced its intention to launch in France in the first quarter of 2014. Its competitors and potential competitors are larger, established and more experienced and have more resources than the Company or its partners. Durasert, Medidur, Tethadur and BioSilicon are its trademarks.
» More Articles for NAS:PSDV

Headlines

Articles On GuruFocus.com
Weekly CEO Sales Highlight: pSivida Corp., Equity Residential, Ciena Corp., Sabre Corp. Dec 28 2015 
pSivida Ltd. Reports Operating Results (10-Q) Feb 10 2011 
pSivida Ltd. Reports Operating Results (10-Q) Nov 09 2010 
pSivida Ltd. Reports Operating Results (10-K) Sep 27 2010 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2010 
pSivida Ltd. Reports Operating Results (10-Q) Feb 12 2010 
pSivida Ltd. Reports Operating Results (10-Q) Nov 13 2009 
pSivida Ltd. Reports Operating Results (10-K) Sep 25 2009 
pSivida Ltd. Reports Operating Results (10-Q) May 13 2009 
pSivida Ltd. Reports Operating Results (10-Q) Feb 11 2009 

More From Other Websites
PSIVIDA CORP. Files SEC form 8-K, Change in Directors or Principal Officers Feb 09 2016
Edited Transcript of PSDV earnings conference call or presentation 8-Feb-16 9:30pm GMT Feb 09 2016
pSivida Corp Earnings Call scheduled for 4:30 pm ET today Feb 08 2016
PSivida reports 2Q loss Feb 08 2016
PSivida reports 2Q loss Feb 08 2016
PSIVIDA CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 08 2016
pSivida Corp. Provides Company Update and Reports Second Quarter FY 2016 Results Feb 08 2016
Q2 2016 pSivida Corp Earnings Release - After Market Close Feb 08 2016
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference... Feb 01 2016
pSivida Corp Announces Second Quarter Fiscal Year 2016 Financial Results Release Date and Conference... Feb 01 2016
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 Jan 28 2016
pSivida CEO to Present at 18th Annual Bio CEO & Investor Conference February 9 Jan 28 2016
pSivida Closes $17.8 Million Offering Jan 13 2016
pSivida Closes $17.8 Million Offering Jan 13 2016
PSIVIDA CORP. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jan 08 2016
pSivida Announces Pricing of $16 Million Public Offering of Common Stock Jan 07 2016
pSivida Announces Pricing of $16 Million Public Offering of Common Stock Jan 07 2016
pSivida Announces Proposed Public Offering of Common Stock Jan 06 2016
pSivida Announces Proposed Public Offering of Common Stock Jan 06 2016
pSivida shares hit new high on plans to file for European drug approval Dec 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK